BioNTech SE (ETR:22UA)
Germany
· Delayed Price · Currency is EUR 86.05
-1.05 (-1.21%)
Last updated: May 28, 2025
BioNTech SE Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,746 | 2,751 | 3,819 | 17,311 | 18,977 | 482.3 | Upgrade
|
| Revenue Growth (YoY) | 0.61% | -27.96% | -77.94% | -8.78% | 3834.63% | 344.11% | Upgrade
|
| Cost of Revenue | 566 | 541.3 | 599.8 | 2,995 | 2,912 | 59.3 | Upgrade
|
| Gross Profit | 2,180 | 2,210 | 3,219 | 14,316 | 16,065 | 423 | Upgrade
|
| Selling, General & Admin | 587 | 599 | 557.7 | 541.2 | 327.2 | 108.5 | Upgrade
|
| Research & Development | 2,272 | 2,254 | 1,783 | 1,537 | 949.2 | 645 | Upgrade
|
| Other Operating Expenses | 597.8 | 642.1 | -93.4 | 319.1 | -57.7 | -9.1 | Upgrade
|
| Operating Expenses | 3,457 | 3,495 | 2,247 | 2,397 | 1,219 | 744.4 | Upgrade
|
| Operating Income | -1,277 | -1,286 | 971.8 | 11,918 | 14,847 | -321.4 | Upgrade
|
| Interest Expense | -15.8 | -12.6 | -7.9 | -18.9 | -27.3 | -2 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 1.5 | 1.6 | Upgrade
|
| Currency Exchange Gain (Loss) | 38.3 | 100.4 | -268 | 792.4 | 512.5 | -42.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 581.4 | 633.7 | 519.6 | 265.3 | -277.8 | -20.4 | Upgrade
|
| EBT Excluding Unusual Items | -672.9 | -564 | 1,216 | 12,957 | 15,055 | -384.8 | Upgrade
|
| Legal Settlements | -118.4 | -113.7 | -29.4 | -3 | -9 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 239 | Upgrade
|
| Pretax Income | -791.3 | -677.7 | 1,186 | 12,954 | 15,046 | -145.8 | Upgrade
|
| Income Tax Expense | -25.3 | -12.4 | 255.8 | 3,520 | 4,754 | -161 | Upgrade
|
| Earnings From Continuing Operations | -766 | -665.3 | 930.3 | 9,434 | 10,293 | 15.2 | Upgrade
|
| Net Income to Company | - | -665.3 | 930.3 | 9,434 | 10,293 | 15.2 | Upgrade
|
| Net Income | -766 | -665.3 | 930.3 | 9,434 | 10,293 | 15.2 | Upgrade
|
| Net Income to Common | -766 | -665.3 | 930.3 | 9,434 | 10,293 | 15.2 | Upgrade
|
| Net Income Growth | - | - | -90.14% | -8.34% | 67613.82% | - | Upgrade
|
| Shares Outstanding (Basic) | 240 | 240 | 241 | 243 | 244 | 235 | Upgrade
|
| Shares Outstanding (Diluted) | 240 | 240 | 243 | 250 | 260 | 249 | Upgrade
|
| Shares Change (YoY) | -0.51% | -0.95% | -2.84% | -3.81% | 4.51% | 17.49% | Upgrade
|
| EPS (Basic) | -3.19 | -2.77 | 3.87 | 38.78 | 42.18 | 0.06 | Upgrade
|
| EPS (Diluted) | -3.19 | -2.77 | 3.83 | 37.77 | 39.63 | 0.06 | Upgrade
|
| EPS Growth | - | - | -89.86% | -4.69% | 65950.00% | - | Upgrade
|
| Free Cash Flow | -532.6 | -78.8 | 5,121 | 13,248 | 762.2 | -79.5 | Upgrade
|
| Free Cash Flow Per Share | -2.22 | -0.33 | 21.10 | 53.03 | 2.94 | -0.32 | Upgrade
|
| Gross Margin | 79.39% | 80.32% | 84.29% | 82.70% | 84.66% | 87.70% | Upgrade
|
| Operating Margin | -46.49% | -46.73% | 25.45% | 68.85% | 78.23% | -66.64% | Upgrade
|
| Profit Margin | -27.89% | -24.18% | 24.36% | 54.50% | 54.24% | 3.15% | Upgrade
|
| Free Cash Flow Margin | -19.39% | -2.86% | 134.10% | 76.53% | 4.02% | -16.48% | Upgrade
|
| EBITDA | -1,020 | -1,033 | 1,110 | 11,983 | 14,893 | -289 | Upgrade
|
| EBITDA Margin | -37.14% | -37.55% | 29.07% | 69.22% | 78.48% | -59.92% | Upgrade
|
| D&A For EBITDA | 256.9 | 252.4 | 138.2 | 64.5 | 46.2 | 32.4 | Upgrade
|
| EBIT | -1,277 | -1,286 | 971.8 | 11,918 | 14,847 | -321.4 | Upgrade
|
| EBIT Margin | -46.49% | -46.73% | 25.45% | 68.85% | 78.23% | -66.64% | Upgrade
|
| Effective Tax Rate | - | - | 21.57% | 27.17% | 31.60% | - | Upgrade
|
| Revenue as Reported | - | - | - | - | 18,977 | 482.3 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.